eMERGE IV Northwest: A partnership to evaluate the use of genomic information in the health care of diverse participants
eMERGE IV Northwest: A partnership to evaluate the use of genomic information in the health care of diverse participants
批准号:
10662312
负责人:
David Russell Crosslin
金额:
$129.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-09-01 至 2025-04-30
关键词:
3-DimensionalAddressAdoptedAdultAlaska NativeAsian ancestryCaringClinicalClinical ResearchClinical Trials NetworkCollaborationsColorectal CancerCoronary ArteriosclerosisDataDedicationsDevelopmentDisciplineDiseaseEconomicsEducationEducation and OutreachEffectivenessElectronic Health RecordElectronicsEnrollmentEnvironmental Risk FactorEthicsEthnic PopulationEvaluationFamilyFamily health statusGeneticGenetic RiskGenomic medicineGenomicsGenotypeGlaucomaHealthHealth systemHealthcareInformaticsInterventionLeadershipLearningMachine LearningMeasuresMedicalMedicineMethodsMissionMorbidity - disease rateMulti-Institutional Clinical TrialNative AmericansNatural Language ProcessingOsteoporosisOutcomeOutcome MeasurePacific IslanderParticipantPathogenicityPatientsPenetrancePerformancePharmacogeneticsPhenotypePopulationPopulation HeterogeneityPrimary CareProcessProviderPublishingRaceRecording of previous eventsRiskRisk AssessmentRisk FactorsRisk ManagementSexual and Gender MinoritiesSiteUnderrepresented PopulationsUniversitiesVariantWashingtonaggregation factorclinical careclinical decision supportclinical practicecohortdata curationdesigneconomic outcomeeconomic valueethical, legal, and social implicationgenetic risk assessmentgenome wide association studygenome-widegenomic datahigh riskimplementation evaluationimplementation scienceimprovedinnovationmalignant breast neoplasmmedical specialtiesmortalitynon-geneticnovelonline resourcepolygenic risk scorepreventrisk predictionscreeningsocial health determinantssupport toolstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Abstract
eMERGE IV (E4) proposes to investigate the implementation of 15 “genomic risk assessment” (GRA) scores in
a network-wide set of diverse participants. These GRAs will include polygenic risk score (PRS) information, as
well as risk information, such as personal and family health history, environmental and social health
determinants, and physical and lab measures. The GRA will aggregate these factors into a single score to
identify those who would benefit from screening and other interventions.
Substantial challenges must be addressed before genomic medicine is a part of standard medical care. We will
collaborate to refine multi-ancestry GRAs and support the inclusion of non-genetic risk factors extracted from
the electronic health record with innovative natural language processing approaches and apply them in a
cohort enriched for Asian ancestry, and sexual and gender minorities. The specific aims of our proposal are
designed to use an implementation science approach to advance the integration of genomic data into clinical
practice, including evaluation of patient perspectives and economic outcomes, and broadening the impact of
eMERGE through collaborations. The University of Washington Medicine dedication to preventative health in a
learning health system and broad expertise across genomics, statistical, ethical, informatic, implementation,
outcomes and economic disciplines will support this multi-site clinical trial.
Specific Aims:
Aim 1: Refine GRA scores and outcomes measures for five high impact conditions, considering stakeholder
input, for implementation in the electronic health record. The conditions are: colorectal cancer, breast cancer,
osteoporosis, coronary artery disease, and glaucoma.
Aim 2: Integrate 15 GRA scores and electronic clinical decision support for management into clinical care and
the EHR and capture clinical outcomes.
Aim 3: Evaluate the implementation, effectiveness, and economic utility of GRA result return.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer.
FamilyTalk 随机对照试验:患者报告的结直肠癌临床基因测序结果。
DOI:
10.1007/s10552-021-01398-1
发表时间:
2021
期刊:
Cancer causes & control : CCC
影响因子:
--
作者:
[Makhnoon,Sukh, Bowen,DeborahJ, Shirts,BrianH, Fullerton,StephanieM, Larson,EricB, Ralston,JamesD, Leppig,KathleenA, Crosslin,DavidR, Veenstra,David, Jarvik,GailP]
通讯作者:
Jarvik,GailP
DOI:
10.1186/s13073-015-0181-z
发表时间:
2015
期刊:
Genome medicine
影响因子:
12.3
作者:
[Crosslin DR, Robertson PD, Carrell DS, Gordon AS, Hanna DS, Burt A, Fullerton SM, Scrol A, Ralston J, Leppig K, Hartzler A, Baldwin E, Andrade Md, Kullo IJ, Tromp G, Doheny KF, Ritchie MD, Crane PK, Nickerson DA, Larson EB, Jarvik GP]
通讯作者:
Jarvik GP
DOI:
10.1177/1556264616667126
发表时间:
2016
期刊:
Journal of empirical research on human research ethics : JERHRE
影响因子:
--
作者:
[Richards,JulieE, Bane,Emmi, Fullerton,StephanieM, Ludman,EvetteJ, Jarvik,Gail]
通讯作者:
Jarvik,Gail
DOI:
10.4172/2090-4924.1000113
发表时间:
2015-07
期刊:
International journal of biomedical data mining
影响因子:
--
作者:
[K. Borthwick;D. Smelser;Jonathan A. Bock;J. Elmore;Evan J. Ryer;Z. Ye;J. Pacheco;D. Carrell;M. Michalkiewicz;William K. Thompson;Jyotishman Pathak;S. Bielinski;J. Denny;J. Linneman;P. Peissig;A. Kho;O. Gottesman;Harpreet Parmar;I. Kullo;C. McCarty;E. Böttinger;E. Larson;G. Jarvik;J. Harley;T. Bajwa;D. P. Franklin;D. Carey;H. Kuivaniemi;G. Tromp]
通讯作者:
K. Borthwick;D. Smelser;Jonathan A. Bock;J. Elmore;Evan J. Ryer;Z. Ye;J. Pacheco;D. Carrell;M. Michalkiewicz;William K. Thompson;Jyotishman Pathak;S. Bielinski;J. Denny;J. Linneman;P. Peissig;A. Kho;O. Gottesman;Harpreet Parmar;I. Kullo;C. McCarty;E. Böttinger;E. Larson;G. Jarvik;J. Harley;T. Bajwa;D. P. Franklin;D. Carey;H. Kuivaniemi;G. Tromp
DOI:
10.1002/mgg3.259
发表时间:
2017-03
期刊:
Molecular genetics & genomic medicine
影响因子:
2
作者:
[Leppig KA, Thiese HA, Carrel D, Crosslin DR, Dorschner MO, Gordon AS, Hartzler A, Ralston J, Scrol A, Larson EB, Jarvik GP]
通讯作者:
Jarvik GP
共 14 条
eMERGE SARS-CoV-2 Supplement: Pulmonary, renal, and inflammatory components
-
批准号:10164629
-
项目类别:
-
资助金额:$37.52万
-
财政年份:2020
-
负责人:David Russell Crosslin
-
依托单位:
eMERGE IV Northwest: A partnership to evaluate the use of genomic information in the health care of diverse participants
-
批准号:10207713
-
项目类别:
-
资助金额:$168.24万
-
财政年份:2015
-
负责人:David Russell Crosslin
-
依托单位:
eMERGE IV Northwest: A partnership to evaluate the use of genomic information in the health care of diverse participants
-
批准号:10447759
-
项目类别:
-
资助金额:$154.85万
-
财政年份:2015
-
负责人:David Russell Crosslin
-
依托单位:
海外基金